secwatch.observer — SEC 8-K summary
======================================

Issuer:     JOHNSON & JOHNSON (JNJ)
CIK:        0000200406
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0000200406-25-000201
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

JNJ reports Q3 adjusted EPS $2.80; plans to spin off Orthopaedics as DePuy Synthes
--------------------------------------------------------------------------------

- Q3 revenue $23,993M (+6.8% YoY); GAAP EPS $2.12, adjusted EPS $2.80 (+15.7% YoY).
- Innovative Medicine sales $15,563M (+6.8% operational); MedTech sales $8,430M (+6.8% operational).
- Intends to separate Orthopaedics business into standalone DePuy Synthes; FY2024 ortho sales ~$9.2B.
- Target completion in 18-24 months; Namal Nawana appointed Worldwide President of DePuy Synthes.
- Separation aims to shift MedTech portfolio to higher-growth/margin markets; JNJ retains focus on six growth areas.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/200406/000020040625000201/0000200406-25-000201-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/200406/000020040625000201/jnj-20251014.htm
  HTML page:      https://secwatch.observer/filing/0000200406-25-000201

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer